TWM
RXRX icon

TriaGen Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

TriaGen Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$59.5K Hold
14,400
– – 0.01% 189
2026
Q2 		$52.8K Buy
+14,400
New +$47.9K 0.01% 185

Other funds holding RXRX

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
QPBE
Quintet Private Bank (Europe) Luxembourg $2.28B AUM 23.89% 1-Year Est. Return

TriaGen Wealth Management's RXRX Position: Q3 2026 in Review

TriaGen Wealth Management held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 14,400 shares worth $59.5K. The position accounts for 0.01% of the portfolio, ranked #189.

TriaGen Wealth Management first reported a position in RXRX in Q2 2026 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • TriaGen Wealth Management held 14,400 shares of Recursion Pharmaceuticals worth $59.5K as of Q3 2026.
  • TriaGen Wealth Management left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
  • Recursion Pharmaceuticals made up 0.01% of TriaGen Wealth Management's portfolio in Q3 2026, its #189 holding.
  • TriaGen Wealth Management first reported a position in Recursion Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on TriaGen Wealth Management's 13F filing for Q3 2026, filed 14 Oct 2026.